Response Prediction in Oncology Clinical Trials
About this webinar
The failure rate of late-stage oncology clinical trials is one of the highest across therapeutic areas, whereas many promising early-stage studies may be prematurely abandoned due to presumably false negative results.
With artificial intelligence (AI) and technology, the relationship between tumour changes and tumour assessment endpoints (ORR, PFS etc.) can be modelled to enhance understanding of the drug mechanism of action in clinical oncology studies.
Join this webinar to meet IAG’s expert team and discuss the latest technological innovations and advanced imaging to support success of oncology clinical trials through quantitative insights.
Who should attend
- Protocol Development Team & Regulatory Submission Strategists
- Pharmaceutical and Biotech executive teams
- Chief Medical Officer
- Chief Scientific Officer
- Principal Investigators and Key Opinion Leaders
- Radiologists
- Medical Directors and Medical Leads
- Clinical Researchers
What you will learn
- Using quantitative imaging methods to address the fundamental limitations of:
- RECIST (Response Evaluation Criteria in Solid Tumours)
- RANO (Response Assessment in Neuro-Oncology)
- mRANO (Modified Radiographic Response Assessment in Neuro-Oncology)
- Advanced quantitative insights into tumour characteristics
- New techniques and their emergence in clinical trials
- Deployment of multi-parametric approach for prediction of response
- A cloud platform for robust imaging data management — DYNAMIKA
Featured Speakers
Professor Sotirios Bisdas, MD, PhD, MSc
Prof. Bisdas is the Head of Neuro-Oncology and Neurology clinical research at IAG, a neuroradiologist and Senior Lecturer at the Institute of Neurology, UCL, London, UK and Professor in Radiology at the University of Tübingen, Germany. Prof. Bisdas is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions.
Dr. Anitha Singareddy, MD
Dr. Singareddy is the Head of Medical Affairs at IAG, a board-certified physician with more than 13 years of experience in clinical research and CRO industry with extensive experience in oncology and haematology clinical trials (medical imaging).
Her expertise includes medical imaging, implementation of study protocols, and implementation of complex scientific assessment criteria in oncology, haematology, and other indications and their respective assessment criteria.
Julia O’Lynn
Julia is Director of Imaging at IAG with extensive expertise in radiologic cross-sectional imaging, Julia has in-depth expertise in clinical trial design, advising life science companies how to use imaging-based markers to accelerate their drug development and ensure standardized imaging across multi-center trials.
Partner for this event
IAG, Image Analysis Group
IAG, Image Analysis Group is a leading medical imaging expert company driving the use of quantitative imaging as an early evidence for drug development. We improve speed and reproducibility of radiological reviews with Computer-Aided workflows and bring smart often AI driven methodologies to extract the full spectrum of information from medical images. Thus, giving biotech or pharma companies early powerful efficacy data in clinical trials.
Learn more: www.ia-grp.com
Reach out: [email protected]
